[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532461":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":22,"centralContacts":26,"locations":34,"responsibleParty":63,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"o Patient cohort",null,"Patient with moleculary proven mitochondrial disorder",{"label":13,"type":10,"description":14,"interventionNames":10},"o Control cohort","People without moleculary proven mitochondrial disorder",[16,20],{"type":17,"name":18,"description":19,"armGroupLabels":10,"otherNames":10},"PROCEDURE","Patient cohort","Collection of 6 blood tubes at the inclusion visit.",{"type":17,"name":21,"description":19,"armGroupLabels":10,"otherNames":10},"Control cohort",[23],{"name":24,"affiliation":5,"role":25},"Aurélien TRIMOUILLE, MD","PRINCIPAL_INVESTIGATOR",[27,31],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","+335 57 82 10 49","aurelien.trimouille@chu-bordeaux.fr",{"name":32,"role":28,"phone":10,"phoneExt":10,"email":33},"Johan Garaude, MD","johan.garaude@inserm.fr",[35,49],{"facility":36,"status":37,"city":38,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Chu Bordeaux","RECRUITING","Bordeaux","France","FR",{"type":42,"coordinates":43},"Point",[44,45],-0.58046,44.84124,{"lat":45,"lon":44},[48],{"name":24,"role":28,"phone":10,"phoneExt":10,"email":10},{"facility":50,"status":51,"city":52,"state":10,"zip":53,"country":39,"countryCode":40,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Hopital Toulouse","NOT_YET_RECRUITING","Toulouse","31059",{"type":42,"coordinates":55},[56,57],1.44367,43.60426,{"lat":57,"lon":56},[60],{"name":61,"role":28,"phone":10,"phoneExt":10,"email":62},"Olivier PATAT, MD","patat.o@chu-toulouse.fr",{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100532461","mitochondrial-disease-associated-immunodeficiencies-100532461",false,"NCT06213103","Mitochondrial Disease-associated ImmunoDeficiencies","Determining the Relevance of Mitochondrial Disease-associated ImmunoDeficiencies - MitoID","MitoID","Inclusion Criteria:\n\n* General inclusion criteria:\n\n  * Patient weighing more than 30kg\n  * Person affiliated with or receiving a social security plan;\n* Patient-specific inclusion criteria:\n\n  * Patient with molecularly proven primary mitochondrial disease\n  * Free, informed, written consent signed by parental authority holders for minor patients and the investigator prior to any examination required by the research and oral and\u002For written assent by the participant (depending on age).\n  * Free, informed consent signed by the patient's representative for adult patients under guardianship and the investigator prior to any examination required by the research.\n  * Free, informed consent signed by the patient of legal age and the investigator prior to any examination required by the research\n* Specific inclusion criteria for controls:\n\n  * Person who has been informed of the purpose of the study and person matched in age (+\u002F- 5 years) and sex to a patient with primary mitochondrial disease at the time of sampling\n  * Free, informed, and signed consent\n  * Person with no known mitochondrial disease\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Refusal to consent to participate in research,\n* Patients for whom molecular causes have not been formally identified (genetic analyses not performed, or no variant or variant of unknown significance after analysis).",true,"ALL","6 Years",{"count":77,"type":78},60,"ESTIMATED","OBSERVATIONAL","The study aims at characterizing the immune dysfunctions in patients with mitochondrial diseases. This has prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies to alleviate disease burden.",[82],"Mitochondrial Disorders",[84,85,86,87,88],"mitochondrial diseases","immunology","PBMCs","scATAC-seq","scRNA-seq","2026-01-30",{"date":91,"type":92},"2026-02-03","ACTUAL",{"date":94,"type":92},"2024-01-30",{"date":96,"type":78},"2028-01",{"name":5,"class":6},2]